Optimizing molecular-targeted therapies in ovarian cancer: The renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways

Journal of Oncology

Volumn , Issue , 2012, Pages

  Hiss, Donavon ^a  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; C REACTIVE PROTEIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; LEWIS X MUCIN DETERMINANT; MAMMALIAN TARGET OF RAPAMYCIN; MATUZUMAB; MUCIN; MUCIN 16; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; SORAFENIB; STAT3 PROTEIN; SUNITINIB; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER CHEMOTHERAPY; FEMALE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84858236146     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/737981     Document Type: Review

References (422)

1. Banerjee S., Gore M., The future of targeted therapies in ovarian cancer Oncologist 2009 14 7 706 716
2. Bast R. C., Hennessy B., Mills G. B., The biology of ovarian cancer: new opportunities for translation Nature Reviews Cancer 2009 9 6 415 428
3. Guarneri V., Piacentini F., Barbieri E., Conte P. F., Achievements and unmet needs in the management of advanced ovarian cancer Gynecologic Oncology 2010 117 2 152 158
4. Itamochi H., Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action World Journal of Biological Chemistry 2010 1 7 209 220
5. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics CA Cancer Journal for Clinicians 2011 61 2 69 90
6. Siegel R., Ward E., Brawley O., Jemal A., Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer Journal for Clinicians 2011 61 4 212 236
7. Anglesio M. S., George J., Kulbe H., Friedlander M., Rischin D., Lemech C., Power J., Coward J., Cowin P. A., House C. M., Chakravarty P., Gorringe K. L., Campbell I. G., Okamoto A., Birrer M. J., Huntsman D. G., Fazio A. D., Kalloger S. E., Balkwill F., Gilks C. B., Bowtell D. D., IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer Clinical Cancer Research 2011 17 8 2538 2548
8. Annunziata C. M., Kohn E. C., Is there a genomic basis for primary chemoresistance in ovarian cancer? Gynecologic Oncology 2003 90 1 1 2 (Pubitemid 37338067)
9. Barrs V., Ouellet V., Lafontaine J., Tonin P. N., Provencher D. M., Mes-Masson A. M., An essential role for Ran GTPase in epithelial ovarian cancer cell survival Molecular Cancer 2010 9, article no. 272
10. Creekmore A. L., Silkworth W. T., Cimini D., Jensen R. V., Roberts P. C., Schmelz E. M., Changes in gene expression and cellular architecture in an ovarian cancer progression model PLoS One 2011 6 3
11. Gmez-Raposo C., Mendiola M., Barriuso J., Hardisson D., Redondo A., Molecular characterization of ovarian cancer by gene-expression profiling Gynecologic Oncology 2010 118 1 88 92
12. Hennessy B. T., Coleman R. L., Markman M., Ovarian cancer The Lancet 2009 374 9698 1371 1382
13. Hubbard S. A., Gargett C. E., A cancer stem cell origin for human endometrial carcinoma? Reproduction 2010 140 1 23 32
14. Husseinzadeh N., Status of tumor markers in epithelial ovarian cancer has there been any progress? A review Gynecologic Oncology 2011 120 1 152 157
15. Jelovac D., Armstrong D. K., Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer Journal for Clinicians 2011 61 3 183 203
16. Kaur T., Slavcev R. A., Wettig S. D., Addressing the challenge: current and future directions in ovarian cancer therapy Current Gene Therapy 2009 9 6 434 458
17. Kwon M. J., Shin Y. K., Epigenetic regulation of cancer-associated genes in ovarian cancer International Journal of Molecular Sciences 2011 12 2 983 1008
18. Nam E. J., Kim Y. T., Alteration of cell-cycle regulation in epithelial ovarian cancer International Journal of Gynecological Cancer 2008 18 6 1169 1182
19. Strauss R., Li Z. Y., Liu Y., Beyer I., Persson J., Sova P., Mller T., Pesonen S., Hemminki A., Hamerlik P., Drescher C., Urban N., Bartek J., Lieber A., Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity PLoS One 2011 6 1
20. Chen J., Wang L., Matyunina L. V., Hill C. G., McDonald J. F., Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells Gynecologic Oncology 2011 121 1 200 205
21. Halon A., Materna V., Drag-Zalesinska M., Nowak-Markwitz E., Gansukh T., Donizy P., Spaczynski M., Zabel M., Dietel M., Lage H., Surowiak P., Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival Pathology and Oncology Research 2011 17 3 1 8
22. Hollier B. G., Evans K., Mani S. A., The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies Journal of Mammary Gland Biology and Neoplasia 2009 14 1 29 43
23. Pliarchopoulou K., Pectasides D., Epithelial ovarian cancer: focus on targeted therapy Critical Reviews in Oncology/Hematology 2010 79 1 17 23
24. Vergara D., Merlot B., Lucot J. P., Collinet P., Vinatier D., Fournier I., Salzet M., Epithelial-mesenchymal transition in ovarian cancer Cancer Letters 2010 291 1 59 66
25. Alvero A. B., Chen R., Fu H. H., Montagna M., Schwartz P. E., Rutherford T., Silasi D. A., Steffensen K. D., Waldstrom M., Visintin I., Mor G., Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance Cell Cycle 2009 8 1 158 166
26. Lis R., Touboul C., Mirshahi P., Ali F., Mathew S., Nolan D. J., Maleki M., Abdalla S. A., Raynaud C. M., Querleu D., Al-Azwani E., Malek J., Mirshahi M., Rafii A., Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12 International Journal of Cancer 2011 128 3 715 725
27. Zhang S., Balch C., Chan M. W., Lai H. C., Matei D., Schilder J. M., Yan P. S., Huang T. H. M., Nephew K. P., Identification and characterization of ovarian cancer-initiating cells from primary human tumors Cancer Research 2008 68 11 4311 4320
28. Boman B. M., Wicha M. S., Cancer stem cells: a step toward the cure Journal of Clinical Oncology 2008 26 17 2795 2799
29. Calorini L., Bianchini F., Environmental control of invasiveness and metastatic dissemination of tumor cells: role of tumor cell-host cell interactions Cell Communication and Signaling 2010 8 24
30. Du H., Taylor H. S., Stem cells and reproduction Current Opinion in Obstetrics and Gynecology 2010 22 3 235 241
31. Ganzinelli M., Mariani P., Cattaneo D., Fossati R., Fruscio R., Corso S., Ricci F., Broggini M., Damia G., Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations European Journal of Cancer 2011 47 7 1086 1094
32. Hermann P. C., Bhaskar S., Cioffi M., Heeschen C., Cancer stem cells in solid tumors Seminars in Cancer Biology 2010 20 2 77 84
33. Liu H. G., Chen C., Yang H., Pan Y. F., Zhang X. H., Cancer stem cell subsets and their relationships Journal of Translational Medicine 2011 9 50
34. Moserle L., Ghisi M., Amadori A., Indraccolo S., Side population and cancer stem cells: therapeutic implications Cancer Letters 2010 288 1 1 9
35. Rogers L. R., Wicha M., Rajasekhar V. K., Vemuri M. C., Therapeutic approaches to target cancer stem cells Regulatory Networks in Stem Cells 2009 New York, NY, USA Humana Press 545 560
36. Santin A. D., Prospective identification and characterization of ovarian cancer stem cells: implications for the treatment of chemotherapy resistant/recurrent ovarian disease Cell Cycle 2009 8 1 3
37. Wu H.-C., Chang D.-K., Huang C.-T., Targeted Therapy for Cancer Journal of Cancer Molecules 2006 2 2 57 66
38. Zhou B.-B. S., Zhang H., Damelin M., Geles K. G., Grindley J. C., Dirks P. B., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery Nature Reviews Drug Discovery 2009 8 10 806 823
39. Bast R. C., Mills G. B., Personalizing therapy for ovarian cancer: BRCAness and beyond Journal of Clinical Oncology 2010 28 22 3545 3548
40. Agarwal R., Gourley C., Perren T. J., Reed N., Parkin D. E., Carty K., Rustin G. J. S., Gabra H., Paul J., Gore M. E., Kaye S. B., First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series European Journal of Cancer 2010 46 11 2020 2026
41. Rowan K., Intraperitoneal therapy for ovarian cancer: why has it not become standard? Journal of the National Cancer Institute 2009 101 11 775 777
42. Aletti G. D., Eisenhauer E. L., Santillan A., Axtell A., Aletti G., Holschneider C., Chi D. S., Bristow R. E., Cliby W. A., Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment Gynecologic Oncology 2011 120 1 23 28
43. Fotopoulou C., Richter R., Braicu I. E., Schmidt S. C., Neuhaus P., Lichtenegger W., Sehouli J., Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer Annals of Surgical Oncology 2010 18 1 1 9
44. Frenel J. S., Leux C., Pouplin L., Ferron G., Berton-Rigaud D., Bourbouloux E., Dravet F., Jaffre I., Classe J. M., Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients Journal of Surgical Oncology 2011 103 1 10 16
45. Fruscio R., Garbi A., Parma G., Lissoni A. A., Garavaglia D., Bonazzi C. M., Dell'Anna T., Mangioni C., Milani R., Colombo N., Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer Journal of the National Cancer Institute 2011 103 4 347 351
46. Ramirez I., Chon H. S., Apte S. M., The role of surgery in the management of epithelial ovarian cancer Cancer Control 2011 18 1 22 30
47. Foster T., Brown T. M., Chang J., Menssen H. D., Blieden M. B., Herzog T. J., A review of the current evidence for maintenance therapy in ovarian cancer Gynecologic Oncology 2009 115 2 290 301
48. Hess L. M., Rong N., Monahan P. O., Gupta P., Thomaskutty C., Matei D., Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer Cancer 2010 116 22 5251 5260
49. Kaye S. B., Colombo N., Monk B. J., Tjulandin S., Kong B., Roy M., Chan S., Filipczyk-Cisarz E., Hagberg H., Vergote I., Lebedinsky C., Parekh T., Santabrbara P., Park Y. C., Nieto A., Poveda A., Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Annals of Oncology 2011 22 1 49 58
50. Kunos C. A., Sill M. W., Buekers T. E., Walker J. L., Schilder J. M., Yamada S. D., Waggoner S. E., Mohiuddin M., Fracasso P. M., Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group Gynecologic Oncology 2010 120 2 224 228
51. O'Malley D. M., Richardson D. L., Rheaume P. S., Salani R., Eisenhauer E. L., McCann G. A., Fowler J. M., Copeland L. J., Cohn D. E., Backes F. J., Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer Gynecologic Oncology 2011 121 2 269 272
52. Rizvi I., Celli J. P., Evans C. L., Abu-Yousif A. O., Muzikansky A., Pogue B. W., Finkelstein D., Hasan T., Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer Cancer Research 2010 70 22 9319 9328
53. Sarosy G. A., Hussain M. M., Seiden M. V., Fuller A. F., Nikrui N., Goodman A., Minasian L., Reed E., Steinberg S. M., Kohn E. C., Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer Cancer 2010 116 6 1476 1484
54. Sehouli J., Stengel D., Harter P., Kurzeder C., Belau A., Bogenrieder T., Markmann S., Mahner S., Mueller L., Lorenz R., Nugent A., Wilke J., Kuznik A., Doering G., Wischnik A., Sommer H., Meerpohl H. -G., Schroeder W., Lichtenegger W., Oskay-Oezcelik G., Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group Journal of Clinical Oncology 2011 29 2 242 248
55. Vencken P. M., Kriege M., Hoogwerf D., Beugelink S., van der Burg M. E.L., Hooning M. J., Berns E. M., Jager A., Collée M., Burger C. W., Seynaeve C., Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients Annals of Oncology 2011 22 6 1346 1352
56. Chon H. S., Lancaster J. M., Microarray-based gene expression studies in ovarian cancer Cancer Control 2011 18 1 8 15
57. Cragun J. M., Screening for ovarian cancer Cancer Control 2011 18 1 16 21
58. Cramer D. W., Bast R. C. Jr., Berg C. D., Diamandis E. P., Godwin A. K., Hartge P., Lokshin A. E., Lu K. H., McIntosh M. W., Mor G., Patriotis C., Pinsky P. F., Thornquist M. D., Scholler N., Skates S. J., Sluss P. M., Srivastava S., Ward D. C., Zhang Z., Zhu C. S., Urban N., Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens Cancer Prevention Research 2011 4 3 365 374
59. Donach M., Yu Y., Artioli G., Banna G., Feng W., Bast R. C., Zhang Z., Nicoletto M. O., Combined use of biomarkers for detection of ovarian cancer in high-risk women Tumor Biology 2010 31 3 209 215
60. Dorn J., Magdolen V., Gkazepis A., Gerte T., Harlozinska A., Sedlaczek P., Diamandis E. P., Schuster T., Harbeck N., Kiechle M., Schmitt M., Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival Annals of Oncology 2011 22 8 1783 1790
61. Dutta S., Wang F. Q., Phalen A., Fishman D. A., Biomarkers for ovarian cancer detection and therapy Cancer Biology and Therapy 2010 9 9 666 675
62. Hartge P., Reducing ovarian cancer death rates through screening Cancer 2011 117 3 449 450
63. Jacobs I., Menon U., The Sine Qua Non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples Cancer Prevention Research 2011 4 3 299 302
64. Kim Y. M., Whang D. H., Park J., Kim S. H., Lee S. W., Park H. A., Ha M., Choi K. -H., Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population Clinical Chemistry and Laboratory Medicine 2011 49 3 527 534
65. Kristedja T. S., Morgan R. J., Cristea M., Targeted agents in ovarian cancer Women's Health 2010 6 5 679 694
66. Ledermann J. A., Marth C., Carey M. S., Birrer M., Bowtell D. D.L., Kaye S., McNeish I., Oza A., Scambia G., Rustin G., Stehman F. B., Gershenson D., Thomas G., Berns E., Casado A., Ottevanger N., Hilpert F., Kim B. -G., Okamoto A., Bacon M., Kitchener H., Stuart G. C.E., Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer International Journal of Gynecological Cancer 2011 21 4 763 770
67. Lee J. H., Park K., Chung Y. J., So H., Kim K., Park J., Oh M., Jo M., Choi K., Lee E. -J., Choi Y. -L., Song S. Y., Bae D. -S., Kim B. -G., Lee J. -H., AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration Experimental and Molecular Medicine 2011 43 2 91 100
68. Leskel S., Leandro-Garca L. J., Mendiola M., Barriuso J., Inglada-Pérez L., Muoz I., Martnez-Delgado B., Redondo A., De Santiago J., Robledo M., Hardisson D., Rodrguez-Antona C., The miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients Endocrine-Related Cancer 2011 18 1 85 95
69. Liu N., Wang X., Sheng X., 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis Current Opinion in Obstetrics and Gynecology 2010 23 1 19 23
70. Mitchell C. L., O'connor J. P. B., Jackson A., Parker G. J. M., Roberts C., Watson Y., Cheung S., Davies K., Buonaccorsi G. A., Clamp A. R., Hasan J., Byrd L., Backen A., Dive C., Jayson G. C., Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy Annals of Oncology 2010 21 10 1982 1989
71. Rein B. J.D., Gupta S., Dada R., Safi J., Michener C., Agarwal A., Potential markers for detection and monitoring of ovarian cancer Journal of Oncology 2011 2011 17
72. Ren J., Cai H., Li Y., Zhang X., Liu Z., Wang J. S., Hwa Y. L., Zhang Y., Yang Y., Li Y., Jiang S. W., Tumor markers for early detection of ovarian cancer Expert Review of Molecular Diagnostics 2010 10 6 787 798
73. Zhu C. S., Pinsky P. F., Cramer D. W., Ransohoff D. F., Hartge P., Pfeiffer R. M., Urban N., Mor G., Bast Jr. R. C., Moore L. E., Lokshin A. E., McIntosh M. W., Skates S. J., Vitonis A., Zhang Z., Ward D. C., Symanowski J. T., Lomakin A., Fung E. T., Sluss P. M., Scholler N., Lu K. H., Marrangoni A. M., Patriotis C., Srivastava S., Buys S. S., Berg C. D., A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer Cancer Prevention Research 2011 4 3 375 383
74. Hong J. H., Lee J. K., Park J. J., Lee N. W., Lee K. W., Na J. Y., Expression pattern of the class I homeobox genes in ovarian carcinoma Journal of Gynecologic Oncology 2010 21 1 29 37
75. Li J., Sherman-Baust C. A., Tsai-Turton M., Bristow R. E., Roden R. B., Morin P. J., Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer BMC cancer 2009 9 244
76. Bombardelli L., Cavallaro U., Immunoglobulin-like cell adhesion molecules: novel signaling players in epithelial ovarian cancer International Journal of Biochemistry and Cell Biology 2010 42 5 590 594
77. De Graeff P., Crijns A. P. G., Ten Hoor K. A., Klip H. G., Hollema H., Oien K., Bartlett J. M., Wisman G. B. A., De Bock G. H., De Vries E. G. E., De Jong S., Van Der Zee A. G. J., The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer British Journal of Cancer 2008 99 2 341 349
78. Faratian D., Zweemer A. J.M., Nagumo Y., Sims A. H., Muir M., Dodds M., Mullen P., Um I., Kay C., Hasmann M., Harrison D. J., Langdon S. P., Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies Clinical Cancer Research 2011 17 13 4451 4461
79. Gallo D., Ferlini C., Scambia G., The epithelial-mesenchymal transition and the estrogen-signaling in ovarian cancer Current Drug Targets 2010 11 4 474 481
80. Hernandez L., Hsu S. C., Davidson B., Birrer M. J., Kohn E. C., Annunziata C. M., Activation of NF- B signaling by inhibitor of NF- B kinase increases aggressiveness of ovarian cancer Cancer Research 2010 70 10 4005 4014
81. Hua K., Din J., Cao Q., Feng W., Zhang Y., Yao L., Huang Y., Zhao Y., Feng Y., Estrogen and progestin regulate HIF-1 expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway Oncology Reports 2009 21 4 893 898
82. Ivan M., Matei D., Blockade of FGF signaling: therapeutic promise for ovarian cancer Cancer Biology and Therapy 2010 10 5 505 508
83. Mabuchi S., Hisamatsu T., Kimura T., Targeting mTOR signaling pathway in ovarian cancer Current Medicinal Chemistry 2011 18 19 2960 2968
84. No J. H., Jeon Y. T., Park I. A., Kim Y. B., Kim J. W., Park N. H., Kang S. B., Han J. Y., Lim J. M., Song Y. S., Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer Gynecologic Oncology 2011 121 1 8 12
85. Rose S. L., Kunnimalaiyaan M., Drenzek J., Seiler N., Notch 1 signaling is active in ovarian cancer Gynecologic Oncology 2010 117 1 130 133
86. Su H. Y., Lai H. C., Lin Y. W., Liu C. Y., Chen C. K., Chou Y. C., Lin S. P., Lin W. C., Lee H. Y., Yu M. H., Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway International Journal of Cancer 2010 127 3 555 567
87. Wang J., Cai J., Han F., Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical wnt signaling pathway International Journal of Gynecological Cancer 2011 21 6 981 987
88. White K. L., Rider D. N., Kalli K. R., Knutson K. L., Jarvik G. P., Goode E. L., Genomics of the NF- B signaling pathway: hypothesized role in ovarian cancer Cancer Causes and Control 2011 22 5 785 801
89. Yamamura S., Matsumura N., Mandai M., Huang Z., Oura T., Baba T., Hamanishi J., Yamaguchi K., Kang H. S., Okamoto T., Abiko K., Mori S., Murphy S. K., Konishi I., The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer International Journal of Cancer 2012 130 1 20 28
90. Yeh K. T., Chen T. H., Yang H. W., Aberrant TGFbeta/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer Epigenetics 2011 6 6 727 739
91. Zecchini S., Bombardelli L., Decio A., Bianchi M., Mazzarol G., Sanguineti F., Aletti G., Maddaluno L., Berezin V., Bock E., Casadio C., Viale G., Colombo N., Giavazzi R., Cavallaro U., The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling EMBO Molecular Medicine 2011 3 8 480 494
92. Zhang H. Y., Zhang P. N., Sun H., Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy European Journal of Obstetrics Gynecology and Reproductive Biology 2009 146 1 81 86
93. Zhang X., George J., Deb S., Degoutin J. L., Takano E. A., Fox S. B., Bowtell D. D.L., Harvey K. F., The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene Oncogene 2011 30 25 2810 2822
94. Zhao Z., Liu X. F., Wu H. C., Zou S. B., Wang J. Y., Ni P. H., Chen X. H., Fan Q. S., Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway Cancer Science 2010 101 6 1454 1462
95. Eskander R. N., Randall L. M., Bevacizumab in the treatment of ovarian cancer Biologics: Targets and Therapy 2011 5 1 5
96. Gardner G. J., Jewell E. L., Current and future directions of clinical trials for ovarian cancer Cancer Control 2011 18 1 44 51
97. Mannel R. S., Brady M. F., Kohn E. C., Hanjani P., Hiura M., Lee R., DeGeest K., Cohn D. E., Monk B. J., Michael H., A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study Gynecologic Oncology 2011 122 1 89 94
98. Teoh D. G.K., Secord A. A., Antiangiogenic therapies in epithelial ovarian cancer Cancer Control 2011 18 1 31 43
99. Anglesio M. S., Carey M. S., Kbel M., MacKay H., Huntsman D. G., Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, June 24th, 2010 Gynecologic Oncology 2011 121 2 407 415
100. Han C. H., Huang Y. J., Lu K. H., Liu Z., Mills G. B., Wei Q., Wang L., Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer Journal of Experimental amp; Clinical Cancer Research 2011 30 1 5
101. Konecny M., Milly M., Zavodna K., Weismanova E., Gregorova J., Mlkva I., Ilencikova D., Kausitz J., Bartosova Z., Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia Breast Cancer Research and Treatment 2011 126 1 119 130
102. Konstantinopoulos P. A., Spentzos D., Karlan B. Y., Taniguchi T., Fountzilas E., Francoeur N., Levine D. A., Cannistra S. A., Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer Journal of Clinical Oncology 2010 28 22 3555 3561
103. Press J. Z., De Luca A., Boyd N., Young S., Troussard A., Ridge Y., Kaurah P., Kalloger S. E., Blood K. A., Smith M., Spellman P. T., Wang Y., Miller D. M., Horsman D., Faham M., Gilks C. B., Gray J., Huntsman D. G., Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities BMC Cancer 2008 8, article no. 17
104. Tinelli A., Malvasi A., Leo G., Vergara D., Pisan M., Ciccarese M., Chiuri V. E., Lorusso V., Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal Cancer and Metastasis Reviews 2010 29 2 339 350
105. Burton E., Chase D., Yamamoto M., De Guzman J., Imagawa D., Berman M. L., Surgical management of recurrent ovarian cancer: the advantage of collaborative surgical management and a multidisciplinary approach Gynecologic Oncology 2011 120 1 29 32
106. Malek A., Tchernitsa O., Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches Methods in Molecular Biology 2010 623 423 436
107. Vergara D., Tinelli A., Martignago R., Malvasi A., Chiuri V. E., Leo G., Biomolecular pathogenesis of borderline ovarian tumors: Focusing target discovery through proteogenomics Current Cancer Drug Targets 2010 10 1 107 116
108. Chang C. L., Ma B., Pang X., Wu T. C., Hung C.-F., Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for vontrol of ovarian cancer Molecular Therapy 2009 17 8 1365 1372
109. Zhang Y. Q., Tsai Y. C., Monie A., Wu T. C., Hung C. F., Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy Molecular Therapy 2010 18 4 692 699
110. Agarwal A., Tressel S. L., Kaimal R., Balla M., Lam F. H., Covic L., Kuliopulos A., Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy Cancer Research 2010 70 14 5880 5890
111. Anborgh P. H., Mutrie J. C., Tuck A. B., Chambers A. F., Role of the metastasis-promoting protein osteopontin in the tumour microenvironment Journal of Cellular and Molecular Medicine 2010 14 8 2037 2044
112. Chan N., Pires I. M., Bencokova Z., Coackley C., Luoto K. R., Bhogal N., Lakshman M., Gottipati P., Oliver F. J., Helleday T., Hammond E. M., Bristow R. G., Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment Cancer Research 2010 70 20 8045 8054
113. Dean E., El-Helw L., Hasan J., Targeted therapies in epithelial ovarian cancer Cancers 2010 2 1 88 113
114. Han E. S., Lin P., Wakabayashi M., Current status on biologic therapies in the treatment of epithelial ovarian cancer Current Treatment Options in Oncology 2009 10 1-2 54 66
115. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation Cell 2011 144 5 646 674
116. Kruse V., Rottey S., De Backer O., Van Belle S., Cocquyt V., Denys H., PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy Acta Clinica Belgica 2011 66 1 2 9
117. Wang Y., Giaccone G., Challenges in cancer molecular targets and therapeutics Frontiers in Oncology 2011 1 article 4 1 3
118. Yuan Y., Liao Y. M., Hsueh C. -T., Mirshahidi H. R., Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP Journal of Hematology and Oncology 2011 4
119. Gioeli D., Gioeli D., The dynamics of the cell signaling network; implications for targeted therapies Targeted Therapies 2011 New York, NY, USA Humana Press 33 53
120. Yap T. A., Carden C. P., Kaye S. B., Beyond chemotherapy: targeted therapies in ovarian cancer Nature Reviews Cancer 2009 9 3 167 181
121. Norquist B. M., Garcia R. L., Allison K. H., Jokinen C. H., Kernochan L. E., Pizzi C. C., Barrow B. J., Goff B. A., Swisher E. M., The molecular pathogenesis of hereditary ovarian carcinoma Cancer 2010 116 22 5261 5271
122. Press J. Z., Wurz K., Norquist B. M., Lee M. K., Pennil C., Garcia R., Welcsh P., Goff B. A., Swisher E. M., Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers Neoplasia 2010 12 12 993 1002
123. Yoshihara K., Tajima A., Adachi S., Quan J., Sekine M., Kase H., Yahata T., Inoue I., Tanaka K., Germline copy number variations in BRCA1-associated ovarian cancer patients Genes Chromosomes and Cancer 2011 50 3 167 177
124. Zhang S., Royer R., Li S., McLaughlin J. R., Rosen B., Risch H. A., Fan I., Bradley L., Shaw P. A., Narod S. A., Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer Gynecologic Oncology 2011 121 2 353 357
125. Bast R. C. Jr., Status of tumor markers in ovarian cancer screening Journal of Clinical Oncology 2003 21 10, supplement 200S 205S
126. Jie S., Medico L., Zhao H., Allelic imbalance in BRCA1 and BRCA2 gene expression and familial ovarian cancer Cancer Epidemiology Biomarkers and Prevention 2011 20 1 50 56
127. Wakefield C. E., Ratnayake P., Meiser B., Suthers G., Price M. A., Duffy J., Tucker K., "For all my family's sake, i should go and find out": an Australian report on genetic counseling and testing uptake in individuals at high risk of breast and/or ovarian cancer Genetic Testing and Molecular Biomarkers 2011 15 6 379 385
128. Fong P. C., Boss D. S., Yap T. A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M. J., Ashworth A., Carmichael J., Kaye S. B., Schellens J. H. M., De Bono J. S., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers New England Journal of Medicine 2009 361 2 123 134
129. Liang H., Tan A. R., PARP inhibitors Current Breast Cancer Reports 2011 3 1 44 54
130. Mangerich A., Brkle A., How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation International Journal of Cancer 2011 128 2 251 265
131. Underhill C., Toulmonde M., Bonnefoi H., A review of PARP inhibitors: from bench to bedside Annals of Oncology 2011 22 2 268 279
132. Weberpals J., Garbuio K., O'Brien A., Clark-Knewks K., Doucette S., Antoniouk O., Gess G., Dimitreulakos J., The DNA repair proteins BECA1 and EECC1 as predictive markers In sporadic ovarian cancer International Journal of Cancer 2009 124 4 806 815
133. Aly A., Ganesan S., BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability Journal of Molecular Cell Biology 2011 3 1 66 74
134. Ashworth A., Drug resistance caused by reversion mutation Cancer Research 2008 68 24 10021 10023
135. Dhillon K. K., Swisher E. M., Taniguchi T., Secondary mutations of BRCA1/2 and drug resistance Cancer Science 2011 102 4 663 669
136. Sakai W., Swisher E. M., Karlan B. Y., Agarwal M. K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D. J., Couch F. J., Urban N., Taniguchi T., Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 2008 451 7182 1116 1120 (Pubitemid 351317449)
137. Swisher E. M., Sakai W., Karlan B. Y., Wurz K., Urban N., Taniguchi T., Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance Cancer Research 2008 68 8 2581 2586 (Pubitemid 351556255)
138. Yap T. A., Sandhu S. K., Carden C. P., de Bono J. S., Poly (ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic CA Cancer Journal for Clinicians 2011 61 1 31 49
139. Rottenberg S., Jaspers J. E., Kersbergen A., Van Der Burg E., Nygren A. O. H., Zander S. A. L., Derksen P. W. B., De Bruin M., Zevenhoven J., Lau A., Boulter R., Cranston A., O'Connor M. J., Martin N. M. B., Borst P., Jonkers J., High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proceedings of the National Academy of Sciences of the United States of America 2008 105 44 17079 17084
140. Chan D. A., Giaccia A. J., Harnessing synthetic lethal interactions in anticancer drug discovery Nature Reviews Drug Discovery 2011 10 5 351 364
141. Peng G., Lin S. Y., Exploiting the homologous recombination DNA repair network for targeted cancer therapy World Journal of Clinical Oncology 2011 2 2 73 79
142. Audeh M. W., Carmichael J., Penson R. T., Friedlander M., Powell B., Bell-McGuinn K. M., Scott C., Weitzel J. N., Oaknin A., Loman N., Lu K., Schmutzler R. K., Matulonis U., Wickens M., Tutt A., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial The Lancet 2010 376 9737 245 251
143. Annunziata C. M., O'Shaughnessy J., Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer Clinical Cancer Research 2010 16 18 4517 4526
144. Boss D. S., Beijnen J. H., Schellens J. H. M., Inducing synthetic lethality using PARP inhibitors Current Clinical Pharmacology 2010 5 3 192 195
145. Brough R., Frankum J. R., Costa-Cabral S., Lord C. J., Ashworth A., Searching for synthetic lethality in cancer Current Opinion in Genetics and Development 2011 21 1 34 41
146. Carden C. P., Yap T. A., Kaye S. B., PARP inhibition: targeting the Achilles'heel of DNA repair to treat germline and sporadic ovarian cancers Current Opinion in Oncology 2010 22 5 473 480
147. Chan S. L., Mok T., PARP inhibition in BRCA-mutated breast and ovarian cancers The Lancet 2010 376 9737 211 213
148. Crawford Y., Ferrara N., Tumor and stromal pathways mediating
149. Dme B., Hendrix M. J. C., Paku S., Tvri J., Tmr J., Alternative vascularization mechanisms in cancer: pathology and therapeutic implications American Journal of Pathology 2007 170 1 1 15 (Pubitemid 47339184)
150. Ferrara N., Pathways mediating VEGF-independent tumor angiogenesis Cytokine and Growth Factor Reviews 2010 21 1 21 26
151. Francavilla C., Maddaluno L., Cavallaro U., The functional role of cell adhesion molecules in tumor angiogenesis Seminars in Cancer Biology 2009 19 5 298 309
152. Raza A., Franklin M. J., Dudek A. Z., Pericytes and vessel maturation during tumor angiogenesis and metastasis American Journal of Hematology 2010 85 8 593 598
153. Spannuth W. A., Sood A. K., Coleman R. L., Angiogenesis as a strategic target for ovarian cancer therapy Nature Clinical Practice Oncology 2008 5 4 194 204 (Pubitemid 351493679)
154. Duhoux F. P., Machiels J. P., Antivascular therapy for epithelial ovarian cancer Journal of Oncology 2010 2010 16
155. Gavalas N. G., Karadimou A., Dimopoulos M. A., Bamias A., Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization Clinical and Developmental Immunology 2010 2010 15
156. Kumaran G. C., Jayson G. C., Clamp A. R., Antiangiogenic drugs in ovarian cancer British Journal of Cancer 2009 100 1 1 7
157. Willmott L. J., Fruehauf J. P., Targeted therapy in ovarian cancer Journal of Oncology 2010 2010 9
158. Coilinson F., Jayson G., New therapeutic agents in ovarian cancer Current Opinion in Obstetrics and Gynecology 2009 21 1 44 53
159. de La Motte Rouge T., Petrella M. C., Michels J., Even C., Balleyguier C., Duclos J., Mazeron R., Morice P., Pautier P., Lhommé C., New drugs and targeted therapeutic agents in ovarian cancer Bulletin du Cancer 2009 96 12 1215 1224
160. Hefler L. A., Zeillinger R., Grimm C., Sood A. K., Cheng W. F., Gadducci A., Tempfer C. B., Reinthaller A., Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer Gynecologic Oncology 2006 103 2 512 517 (Pubitemid 44740099)
161. Rudlowski C., Pickart A. K., Fuhljahn C., Friepoertner T., Schlehe B., Biesterfeld S., Schroeder W., Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up International Journal of Gynecological Cancer 2006 16 1 183 189
162. Burger R. A., Overview of anti-angiogenic agents in development for ovarian cancer Gynecologic Oncology 2011 121 1 230 238
163. Matulonis U. A., Bevacizumab and its use in epithelial ovarian cancer Future Oncology 2011 7 3 365 379
164. Annunziata C. M., Walker A. J., Minasian L., Yu M., Kotz H., Wood B. J., Calvo K., Choyke P., Kimm D., Steinberg S. M., Kohn E. C., Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2 Clinical Cancer Research 2010 16 2 664 672
165. Bodnar L., Grnas M., Szczylik C., Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study Gynecologic Oncology 2011 123 1 33 36
166. Matei D., Sill M. W., Lankes H. A., DeGeest K., Bristow R. E., Mutch D., Yamada S. D., Cohn D., Calvert V., Farley J., Petricoin E. F., Birrer M. J., Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial Journal of Clinical Oncology 2011 29 1 69 75
167. Homsi J., Daud A. I., Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors Cancer Control 2007 14 3 285 294 (Pubitemid 47057799)
168. Shojaei F., Ferrara N., Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies Drug Resistance Updates 2008 11 6 219 230
169. Teicher B. A., Antiangiogenic agents and targets: a perspective Biochemical Pharmacology 2011 81 1 6 12
170. Tortora G., Ciardiello F., Gasparini G., Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications Nature Clinical Practice Oncology 2008 5 9 521 530
171. Gomperts B. D., Kramer I. M., Tatham P. E. R., Signalling pathways operated by receptor protein tyrosine kinases Signal Transduction 2009 San Diego, Calif, USA Academic Press 315 374
172. Nelson J., Single pass growth factor receptors Structure and Function in Cell Signalling 2008 West Sussex, UK Wiley 179 214
173. Bast R. C. Jr., Boyer C. M., Jacobs I., Feng Ji Xu, Wu S., Wiener J., Kohler M., Berchuck A., Cell growth regulation in epithelial ovarian cancer Cancer 1993 71 4 1597 1601 (Pubitemid 23056079)
174. Ciardiello F., Tortora G., Drug therapy: EGFR antagonists in cancer treatment New England Journal of Medicine 2008 358 11 1096 1174
175. Steffensen K. D., Waldstrm M., Jeppesen U., Jakobsen E., Brandslund I., Jakobsen A., The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer International Journal of Gynecological Cancer 2007 17 4 798 807 (Pubitemid 47063320)
176. Baron A. T., Lafky J. M., Boardman C. H., Cora E. M., Buenafe M. C., Liu D., Rademaker A., Fishman D. A., Podratz K. C., Reiter J. L., Maihle N. J., Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer Cancer Treatment and Research 2009 149 189 202
177. Lafky J. M., Wilken J. A., Baron A. T., Maihle N. J., Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer Biochimica et Biophysica Acta. Reviews on Cancer 2008 1785 2 232 265
178. Bolitho C., Hahn M. A., Baxter R. C., Marsh D. J., The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor Endocrine-Related Cancer 2010 17 4 929 940
179. Reimer D., Hubalek M., Riedle S., Skvortsov S., Erdel M., Concin N., Fiegl H., Muller-Holzner E., Marth C., Illmensee K., Altevogt P., Zeimet A. G., E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer Cancer Research 2010 70 11 4613 4623
180. Hudson L. G., Zeineldin R., Silberberg M., Stack M. S., Activated epidermal growth factor receptor in ovarian cancer Cancer Treatment and Research 2009 149 203 226
181. Song L. P., Hammond G. T., Leung P. C. K., Epidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasion Molecular Endocrinology 2009 23 10 1646 1656
182. Tanaka Y., Terai Y., Tanabe A., Sasaki H., Sekijima T., Fujiwara S., Yamashita Y., Kanemura M., Ueda M., Sugita M., Franklin W. A., Ohmichi M., Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer Cancer Biology and Therapy 2011 11 1 50 57
183. Zhou H. Y., Pon Y. L., Wong A. S. T., Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase Endocrinology 2007 148 11 5195 5208 (Pubitemid 350012618)
184. Bookman M. A., Darcy K. M., Clarke-Pearson D., Boothby R. A., Horowitz I. R., Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group Journal of Clinical Oncology 2003 21 2 283 290 (Pubitemid 46606157)
185. Campos S., Hamid O., Seiden M. V., Oza A., Plante M., Potkul R. K., Lenehan P. F., Kaldjian E. P., Varterasian M. L., Jordan C., Charbonneau C., Hirte H., Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer Journal of Clinical Oncology 2005 23 24 5597 5604
186. Gordon A. N., Finkler N., Edwards R. P., Garcia A. A., Crozier M., Irwin D. H., Barrett E., Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study International Journal of Gynecological Cancer 2005 15 5 785 792 (Pubitemid 41783082)
187. Gordon M. S., Matei D., Aghajanian C., Matulonis U. A., Brewer M., Fleming G. F., Hainsworth J. D., Garcia A. A., Pegram M. D., Schilder R. J., Cohn D. E., Roman L., Derynck M. K., Ng K., Lyons B., Allison D. E., Eberhard D. A., Pham T. Q., Dere R. C., Karlan B. Y., Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status Journal of Clinical Oncology 2006 24 26 4324 4332 (Pubitemid 46630791)
188. Palayekar M. J., Herzog T. J., The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer International Journal of Gynecological Cancer 2008 18 5 879 890
189. Reibenwein J., Krainer M., Targeting signaling pathways in ovarian cancer Expert Opinion on Therapeutic Targets 2008 12 3 353 365 (Pubitemid 351419428)
190. Schilder R. J., Sill M. W., Chen X., Darcy K. M., Decesare S. L., Lewandowski G., Lee R. B., Arciero C. A., Wu H., Godwin A. K., Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study Clinical Cancer Research 2005 11 15 5539 5548 (Pubitemid 41060831)
191. Secord A. A., Blessing J. A., Armstrong D. K., Rodgers W. H., Miner Z., Barnes M. N., Lewandowski G., Mannel R. S., Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study Gynecologic Oncology 2008 108 493 499
192. Tang L., Zhao X., Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy Medical Hypotheses 2011 76 4 530 532
193. Wagner U., du Bois A., Pfisterer J., Huober J., Loibl S., Lck H. J., Sehouli J., Gropp M., Sthle A., Schmalfeldt B., Meier W., Jackisch C., Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6) Gynecologic Oncology 2007 105 1 132 137 (Pubitemid 46441449)
194. Zeineldin R., Muller C. Y., Stack M. S., Hudson L. G., Targeting the EGF receptor for ovarian cancer therapy Journal of Oncology 2010 2010 11
195. Elie C., Geay J. F., Morcos M., Le Toerneau A., Girre V., Brot P., Marmey B., Chauvenet L., Audouin J., Pujade-Lauraine E., Camilleri-Brot S., Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group) British Journal of Cancer 2004 91 3 470 475 (Pubitemid 39093565)
196. Nielsen J. S., Jakobsen E., Hlund B., Bertelsen K., Jakobsen A., Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer International Journal of Gynecological Cancer 2004 14 6 1086 1096 (Pubitemid 39603351)
197. Psyrri A., Kassar M., Yu Z., Bamias A., Weinberger P. M., Markakis S., Kowalski D., Camp R. L., Rimm D. L., Dimopoulos M. A., Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer Clinical Cancer Research 2005 11 24 8637 8643 (Pubitemid 43005911)
198. Posadas E. M., Kwitkowski V., Kotz H. L., Espina V., Minasian L., Tchabo N., Premkumar A., Hussain M. M., Chang R., Steinberg S. M., Kohn E. C., A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling Cancer 2007 110 2 309 317 (Pubitemid 47121890)
199. Posadas E. M., Liel M. S., Kwitkowski V., Minasian L., Godwin A. K., Hussain M. M., Espina V., Wood B. J., Steinberg S. M., Kohn E. C., A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer Cancer 2007 109 7 1323 1330 (Pubitemid 46466559)
200. Tsujioka H., Yotsumoto F., Hikita S., Ueda T., Kuroki M., Miyamoto S., Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy Current Opinion in Obstetrics and Gynecology 2011 23 1 24 30
201. Yagi H., Yotsumoto F., Miyamoto S., Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition Molecular Cancer Therapeutics 2008 7 10 3441 3451
202. Bianco R., Garofalo S., Rosa R., Damiano V., Gelardi T., Daniele G., Marciano R., Ciardiello F., Tortora G., Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs British Journal of Cancer 2008 98 5 923 930 (Pubitemid 351341618)
203. Dedes K. J., Wetterskog D., Ashworth A., Kaye S. B., Reis-Filho J. S., Emerging therapeutic targets in endometrial cancer Nature Reviews Clinical Oncology 2011 8 5 261 271
204. Foster H., Coley H. M., Goumenou A., Pados G., Harvey A., Karteris E., Differential expression of mTOR signalling components in drug resistance in ovarian cancer Anticancer Research 2010 30 9 3529 3534
205. Trinh X. B., Tjalma W. A. A., Vermeulen P. B., Van Den Eynden G., Van Der Auwera I., Van Laere S. J., Helleman J., Berns E. M. J. J., Dirix L. Y., Van Dam P. A., The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer British Journal of Cancer 2009 100 6 971 978
206. Alshenawy H. A., Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths Annals of Diagnostic Pathology 2010 14 6 387 395
207. Lim R., Ahmed N., Borregaard N., Riley C., Wafai R., Thompson E. W., Quinn M. A., Rice G. E., Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition International Journal of Cancer 2007 120 11 2426 2434 (Pubitemid 46642130)
208. Morrison J., Briggs S. S., Green N. K., Thoma C., Fisher K. D., Kehoe S., Seymour L. W., Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer Human Gene Therapy 2009 20 3 239 251
209. Sheng Q., Liu J., The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer British Journal of Cancer 2011 104 8 1241 1245
210. Siwak D. R., Carey M., Hennessy B. T., Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges Journal of Oncology 2010 2010 20
211. Chauhan S. C., Kumar D., Jaggi M., Mucins in ovarian cancer diagnosis and therapy Journal of Ovarian Research 2009 2 1, article no. 21
212. Heinzelmann-Schwarz V. A., Gardiner-Garden M., Henshall S. M., Scurry J. P., Scolyer R. A., Smith A. N., Bali A., Vanden Bergh P., Baron-Hay S., Scott C., Fink D., Hacker N. F., Sutherland R. L., O'Brien P. M., A distinct molecular profile associated with mucinous epithelial ovarian cancer British Journal of Cancer 2006 94 6 904 913
213. Jonckheere N., van Seuningen I., The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers Biochimie 2010 92 1 1 11
214. Andersen M. R., Goff B. A., Lowe K. A., Scholler N., Bergan L., Drescher C. W., Paley P., Urban N., Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer Gynecologic Oncology 2010 116 3 378 383
215. Cramer D. W., O'Rourke D. J., Vitonis A. F., Matulonis U. A., DiJohnson D. A., Sluss P. M., Crum C. P., Liu B. C. S., CA125 immune complexes in ovarian cancer patients with low CA125 concentrations Clinical Chemistry 2010 56 12 1889 1892
216. Fleming N. D., Cass I., Walsh C. S., Karlan B. Y., Li A. J., CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer Gynecologic Oncology 2011 121 2 249 252
217. Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., Salvagno G. L., Franchi M., Lippi G., Guidi G. C., The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clinical Chemistry and Laboratory Medicine 2011 49 3 521 525
218. Rauh-Hain J. A., Krivak T. C., del Carmen M. G., Olawaiye A. B., Ovarian cancer screening and early detection in the general population Reviews in Obstetrics and Gynecology 2011 4 1 15 21
219. Shah C. A., Lowe K. A., Paley P., Wallace E., Anderson G. L., McIntosh M. W., Andersen M. R., Scholler N., Bergan L. A., Thorpe J. D., Urban N., Drescher C. W., Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125 Cancer Epidemiology Biomarkers and Prevention 2009 18 5 1365 1372
220. Van Gorp T., Cadron I., Despierre E., Daemen A., Leunen K., Amant F., Timmerman D., De Moor B., Vergote I., HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm British Journal of Cancer 2011 104 5 863 870
221. van Haaften-Day C., Shen Y., Xu F., Yu Y., Berchuck A., Havrilesky L. J., De Bruijn H. W. A., Van Der Zee A. G. J., Bast R. C., Hacker N. F., OVXL, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma a critical appraisal Cancer 2001 92 11 2837 2844 (Pubitemid 33091920)
222. Thériault C., Pinard M., Comamala M., Migneault M., Beaudin J., Matte I., Boivin M., Piché A., Rancourt C., MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis Gynecologic Oncology 2011 121 3 434 443
223. Boivin M., Lane D., Piché A., Rancourt C., CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis Gynecologic Oncology 2009 115 3 407 413
224. Gubbels J. A. A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., Bera T. K., Connor J. P., Sathyanarayana B. K., Lee B., Pastan I., Patankar M. S., Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors Molecular Cancer 2006 5, article no. 50
225. Rump A., Morikawa Y., Tanaka M., Minami S., Umesaki N., Takeuchi M., Miyajima A., Binding of ovarian cancer antigen CA125/MUC61 to mesothelin mediates cell adhesion Journal of Biological Chemistry 2004 279 10 9190 9198 (Pubitemid 38295982)
226. Belisle J. A., Gubbels J. A. A., Raphael C. A., Migneault M., Rancourt C., Connor J. P., Patankar M. S., Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125) Immunology 2007 122 3 418 429 (Pubitemid 47556479)
227. Chen Y., Clark S., Wong T., Chen Y., Chen Y., Dennis M. S., Luis E., Zhong F., Bheddah S., Koeppen H., Gogineni A., Polakis P., Mallet W., Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models Cancer Research 2007 67 10 4924 4932 (Pubitemid 46910200)
228. McQuarrie S. A., Mercer J. R., Syme A., Suresh M. R., Miller G. G., Preliminary results of nanopharmaceuticals used in the radioimmunotheraphy of ovarian cancer Journal of Pharmacy and Pharmaceutical Sciences 2005 7 4 29 34
229. Scholler N., Urban N., CA125 in ovarian cancer Biomarkers in Medicine 2007 1 4 513 523
230. Chekmasova A. A., Rao T. D., Nikhamin Y., Park K. J., Levine D. A., Spriggs D. R., Brentjens R. J., Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen Clinical Cancer Research 2010 16 14 3594 3606
231. Lasaro M. O., Ertl H. C. J., Targeting inhibitory pathways in cancer immunotherapy Current Opinion in Immunology 2010 22 3 385 390
232. Zhang T., Herlyn D., Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer Cancer Immunology, Immunotherapy 2009 58 4 475 492
233. Rachagani S., Torres M. P., Moniaux N., Batra S. K., Current status of mucins in the diagnosis and therapy of cancer BioFactors 2009 35 6 509 527
234. Singh A. P., Senapati S., Ponnusamy M. P., Jain M., Lele S. M., Davis J. S., Remmenga S., Batra S. K., Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer The Lancet Oncology 2008 9 11 1076 1085
235. Edgell T., Martin-Roussety G., Barker G., Autelitano D. J., Allen D., Grant P., Rice G. E., Phase II biomarker trial of a multimarker diagnostic for ovarian cancer Journal of Cancer Research and Clinical Oncology 2010 136 7 1079 1088
236. Xu F. J., Yu Y. H., Daly L., Anselmino L., Hass G. M., Berchuck A., Rodriguez G. C., Soper J. T., Clarke-Pearson D. L., Hollis D., Boyer C., Bast R. C., OVX1 as a marker for early stage endometrial carcinoma Cancer 1994 73 7 1855 1858 (Pubitemid 24101961)
237. Xu F. J., Yu Y. H., Daly L., DeSombre K., Anselmino L., Hass G. M., Berchuck A., Soper J. T., Clarke-Pearson D. L., Boyer C., Layfield L. J., Bast R. C., OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures Journal of Clinical Oncology 1993 11 8 1506 1510 (Pubitemid 23228255)
238. Xu F. J., Yu Y. H., Li B. Y., Moradi M., Elg S., Lane C., Carson L., Ramakrishnan S., Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells Cancer Research 1991 51 15 4012 4019
239. Baxevanis C. N., Perez S. A., Papamichail M., Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy Cancer Immunology, Immunotherapy 2009 58 3 317 324
240. Frey A. B., Monu N., Signaling defects in anti-tumor T cells Immunological Reviews 2008 222 1 192 205 (Pubitemid 351430368)
241. Mathew M., Verma R. S., Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy Cancer Science 2009 100 8 1359 1365
242. Gao L., Yan L., Lin B., Gao J., Liang X., Wang Y., Liu J., Zhang S., Masao I., Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I Journal of Experimental and Clinical Cancer Research 2011 30 1 15
243. Clendenen T. V., Lundin E., Zeleniuch-Jacquotte A., Koenig K. L., Berrino F., Lukanova A., Lokshin A. E., Idahl A., Ohlson N., Hallmans G., Krogh V., Sieri S., Muti P., Marrangoni A., Nolen B. M., Liu M., Shore R. E., Arslan A. A., Circulating inflammation markers and risk of epithelial ovarian cancer Cancer Epidemiology Biomarkers and Prevention 2011 20 5 799 810
244. Giuntoli R. L., Webb T. J., Zoso A., Rogers O., Diaz-Montes T. P., Bristow R. E., Oelke M., Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity Anticancer Research 2009 29 8 2875 2884
245. Kim S., Hagemann A., Demichele A., Immuno-modulatory gene polymorphisms and outcome in breast and ovarian cancer Immunological Investigations 2009 38 3-4 324 340
246. Kulbe H., Thompson R., Wilson J. L., Robinson S., Hagemann T., Fatah R., Gould D., Ayhan A., Balkwill F., The inflammatory cytokine tumor necrosis factor- generates an autocrine tumor-promoting network in epithelial ovarian cancer cells Cancer Research 2007 67 2 585 592 (Pubitemid 46192196)
247. Leizer A. L., Alvero A. B., Fu H. H., Holmberg J. C., Cheng Y. -C., Silasi D. -A., Rutherford T., Mor G., Regulation of inflammation by the NF- B pathway in ovarian cancer stem cells American Journal of Reproductive Immunology 2011 65 4 438 447
248. Lin W. W., Karin M., A cytokine-mediated link between innate immunity, inflammation, and cancer Journal of Clinical Investigation 2007 117 5 1175 1183 (Pubitemid 46718402)
249. Mor G., Yin G., Chefetz I., Yang Y., Alvero A., Ovarian cancer stem cells and inflammation Cancer Biology and Therapy 2011 11 8 708 713
250. Nowak M., Glowacka E., Szpakowski M., Szyllo K., Malinowski A., Kulig A., Tchorzewski H., Wilczynski J., Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors Neuroendocrinology Letters 2010 31 3 375 383
251. Yigit R., Figdor C. G., Zusterzeel P. L.M., Pots J. M., Torensma R., Massuger L. F.A.G., Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer European Journal of Cancer 2011 47 12 1883 1889
252. Bollrath J., Greten F. R., IKK/NF-B and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis EMBO Reports 2009 10 12 1314 1319
253. Duan Z., Ames R. Y., Ryan M., Hornicek F. J., Mankin H., Seiden M. V., CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells Cancer Chemotherapy and Pharmacology 2009 63 4 681 689
254. Duan Z., Foster R., Bell D. A., Mahoney J., Wolak K., Vaidya A., Hampel C., Lee H., Seiden M. V., Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer Clinical Cancer Research 2006 12 17 5055 5063 (Pubitemid 44453331)
255. Grivennikov S., Karin M., Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008 13 1 7 9 (Pubitemid 350309747)
256. Grivennikov S. I., Karin M., Dangerous liaisons: STAT3 and NF- B collaboration and crosstalk in cancer Cytokine and Growth Factor Reviews 2010 21 1 11 19
257. Hodge D. R., Hurt E. M., Farrar W. L., The role of IL-6 and STAT3 in inflammation and cancer European Journal of Cancer 2005 41 16 2502 2512 (Pubitemid 41540626)
258. Yu H., Pardoll D., Jove R., STATs in cancer inflammation and immunity: a leading role for STAT3 Nature Reviews Cancer 2009 9 11 798 809
259. Wang Y., Niu X. L., Qu Y., Wu J., Zhu Y. Q., Sun W. J., Li L. Z., Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells Cancer Letters 2010 295 1 110 123
260. Lane D., Matte I., Rancourt C., Piché A., Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients BMC Cancer 2011 11 210
261. Guo Y., Nemeth J., O'Brien C., Susa M., Liu X., Zhang Z., Choy E., Mankin H., Hornicek F., Duan Z., Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer Clinical Cancer Research 2010 16 23 5759 5769
262. Lo C. W., Chen M. W., Hsiao M., Wang S., Chen C. -A., Hsiao S. -M., Chang J. -S., Lai T. -C., Rose-John S., Kuo M. -L., Wei L. -H., IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer Cancer Research 2011 71 2 424 434
263. Colomiere M., Findlay J., Ackland L., Ahmed N., Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of 6 1 integrin International Journal of Biochemistry and Cell Biology 2009 41 5 1034 1045
264. Colomiere M., Ward A. C., Riley C., Trenerry M. K., Cameron-Smith D., Findlay J., Ackland L., Ahmed N., Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas British Journal of Cancer 2009 100 1 134 144
265. Baud V., Karin M., Is NF- B a good target for cancer therapy? Hopes and pitfalls Nature Reviews Drug Discovery 2009 8 1 33 40
266. Chaturvedi M. M., Sung B., Yadav V. R., Kannappan R., Aggarwal B. B., NF- B addiction and its role in cancer: one size does not fit all Oncogene 2011 30 14 1615 1630
267. Kleinberg L., Dong H. P., Holth A., Risberg B., Trope' C. G., Nesland J. M., Flrenes V. A., Davidson B., Cleaved caspase-3 and nuclear factor- B p65 are prognostic factors in metastatic serous ovarian carcinoma Human Pathology 2009 40 6 795 806
268. Fang X., Yu S., Bast R. C., Liu S., Xu H. J., Hu S. X., LaPushin R., Claret F. X., Aggarwal B. B., Lu Y., Mills G. B., Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells Journal of Biological Chemistry 2004 279 10 9653 9661 (Pubitemid 38296034)
269. Merritt W. M., Lin Y. G., Spannuth W. A., Fletcher M. S., Kamat A. A., Han L. Y., Landen C. N., Jennings N., De Geest K., Langley R. R., Villares G., Sanguino A., Lutgendorf S. K., Lopez-Berestein G., Bar-Eli M. M., Sood A. K., Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth Journal of the National Cancer Institute 2008 100 5 359 372 (Pubitemid 351480526)
270. Schwartz B. M., Hong G., Morrison B. H., Wu W., Baudhuin L. M., Xiao Y. J., Mok S. C., Xu Y., Lysophospholipids increase interleukin-8 expression in ovarian cancer cells Gynecologic Oncology 2001 81 2 291 300 (Pubitemid 32424177)
271. Waugh D. J. J., Wilson C., The interleukin-8 pathway in cancer Clinical Cancer Research 2008 14 21 6735 6741
272. Xu L., Fidler I. J., Interleukin 8: an autocrine growth factor for human ovarian cancer Oncology Research 2000 12 2 97 106
273. Yang J., Wang Y., Gao Y., Shao J., Zhang X. J., Yao Z., Reciprocal regulation of 17 -estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer Cytokine 2009 46 3 382 391
274. Lee L. F., Hellendall R. P., Wang Y., Haskill J. S., Mukaida N., Matsushima K., Ting J. P. Y., IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration Journal of Immunology 2000 164 5 2769 2775 (Pubitemid 30115511)
275. Schmeler K. M., Vadhan-Raj S., Ramirez P. T., Apte S. M., Cohen L., Bassett R. L., Iyer R. B., Wolf J. K., Levenback C. L., Gershenson D. M., Freedman R. S., A phase II study of GM-CSF and rIFN- 1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer Gynecologic Oncology 2009 113 2 210 215
276. Brimo F., Herawi M., Sharma R., Netto G. J., Epstein J. I., Illei P. B., Hepatocyte nuclear factor-1 expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis Human Pathology 2011 42 11 1613 1619
277. Higashiguchi A., Yamada T., Susumu N., Mori T., Suzuki A., Aoki D., Sakamoto M., Specific expression of hepatocyte nuclear factor-1 in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis Cancer Science 2007 98 3 387 391 (Pubitemid 46195610)
278. Kato N., Toukairin M., Asanuma I., Motoyama T., Immunocytochemistry for hepatocyte nuclear factor-1 (HNF-11 ): a marker for ovarian clear cell carcinoma Diagnostic Cytopathology 2007 35 4 193 197 (Pubitemid 46516671)
279. Tsuchiya A., Sakamoto M., Yasuda J., Chuma M., Ohta T., Ohki M., Yasugi T., Taketani Y., Hirohashi S., Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma American Journal of Pathology 2003 163 6 2503 2512 (Pubitemid 37466491)
280. Yamaguchi K., Mandai M., Oura T., Matsumura N., Hamanishi J., Baba T., Matsui S., Murphy S. K., Konishi I., Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes Oncogene 2010 29 12 1741 1752
281. Bouchard D., Morisset D., Bourbonnais Y., Tremblay G. M., Proteins with whey-acidic-protein motifs and cancer Lancet Oncology 2006 7 2 167 174 (Pubitemid 43159503)
282. Li J., Dowdy S., Tipton T., Podratz K., Lu W. G., Xie X., Jiang S. W., HE4 as a biomarker for ovarian and endometrial cancer management Expert Review of Molecular Diagnostics 2009 9 6 555 566
283. Anborgh P. H., Mutrie J. C., Tuck A. B., Chambers A. F., Pre- and post-translational regulation of osteopontin in cancer Journal of Cell Communication and Signaling 2011 5 2 111 122
284. Johnston N. I. F., Gunasekharan V. K., Ravindranath A., O'Connell C., Johnston P. G., El-Tanani M. K., Osteopontin as a target for cancer therapy Frontiers in Bioscience 2008 13 11 4361 4372 (Pubitemid 351599688)
285. Tilli T. M., Franco V. F., Robbs B. K., Wanderley J. L.M., Da Silva F. R.D.A., De Mello K. D., Viola J. P.B., Weber G. F., Gimba E. R., Osteopontin-c splicing isoform contributes to ovarian cancer progression Molecular Cancer Research 2011 9 3 280 293
286. Breidenbach M., Rein D. T., Everts M., Glasgow J. N., Wang M., Passineau M. J., Alvarez R. D., Korokhov N., Curiel D. T., Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy Gene Therapy 2005 12 2 187 193 (Pubitemid 40185922)
287. Yen M. J., Hsu C. Y., Mao T. L., Wu T. C., Roden R., Wang T. L., Shih L. M., Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma Clinical Cancer Research 2006 12 3 827 831 (Pubitemid 43259864)
288. Ahmed N., Oliva K. T., Barker G., Hoffmann P., Reeve S., Smith I. A., Quinn M. A., Rice G. E., Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer Proteomics 2005 5 17 4625 4636 (Pubitemid 41739939)
289. Saldova R., Royle L., Radcliffe C. M., Abd hamid U. M., Evans R., Arnold J. N., Banks R. E., Hutson R., Harvey D. J., Antrobus R., Petrescu S. M., Dwek R. A., Rudd P. M., Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG Glycobiology 2007 17 12 1344 1356 (Pubitemid 350131311)
290. Ye B., Cramer D. W., Skates S. J., Gygi S. P., Pratomo V., Fu L., Horick N. K., Licklider L. J., Schorge J. O., Berkowitz R. S., Mok S. C., Haptoglobin- subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry Clinical Cancer Research 2003 9 8 2904 2911 (Pubitemid 36993248)
291. Zhao C., Annamalai L., Guo C., Kothandaraman N., Koh S. C. L., Zhang H., Biswas A., Choolani M., Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer Neoplasia 2007 9 1 1 7 (Pubitemid 46203929)
292. Kobayashi H., Suzuki M., Kanayama N., Terao T., Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells Journal of Biological Chemistry 2004 279 8 6371 6379 (Pubitemid 38248770)
293. Kobayashi H., Suzuki M., Tanaka Y., Kanayama N., Terao T., A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor- 1 signaling cascade Journal of Biological Chemistry 2003 278 10 7790 7799 (Pubitemid 36800512)
294. Kobayashi H., Yagyu T., Inagaki K., Kondo T., Suzuki M., Kanayama N., Terao T., Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancer International Journal of Cancer 2004 110 1 134 139 (Pubitemid 38507213)
295. Liu J., Guo Q., Chen B., Yu Y., Lu H., Li Y. Y., Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90 FEBS Letters 2006 580 1 245 250 (Pubitemid 43005344)
296. Matsuzaki H., Kobayashi H., Yagyu T., Wakahara K., Kondo T., Kurita N., Sekino H., Inagaki K., Suzuki M., Kanayama N., Terao T., Plasma bikunin as a favorable prognostic factor in ovarian cancer Journal of Clinical Oncology 2005 23 7 1463 1472
297. Suzuki M., Kobayashi H., Tanaka Y., Hirashima Y., Kanayama N., Takei Y., Saga Y., Suzuki M., Itoh H., Terao T., Bikunin target genes in ovarian cancer cells identified by microarray analysis Journal of Biological Chemistry 2003 278 17 14640 14646 (Pubitemid 36799786)
298. Takei Y., Mizukami H., Saga Y., Kobayashi H., Suzuki M., Matsushita T., Ozawa K., Suzuki M., Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro International Journal of Cancer 2005 113 1 54 58 (Pubitemid 39507310)
299. Tanaka Y., Kobayashi H., Suzuki M., Kanayama N., Suzuki M., Terao T., Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer Gynecologic Oncology 2004 94 3 725 734 (Pubitemid 39194467)
300. Basal E., Eghbali-Fatourechi G. Z., Kalli K. R., Hartmann L. C., Goodman K. M., Goode E. L., Kamen B. A., Low P. S., Knutson K. L., Functional folate receptor alpha is elevated in the blood of ovarian cancer patients PLoS One 2009 4 7
301. Cran L. M., Arts H. J., van Oosten M., The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer Cell Oncology 2011
302. Kalli K. R., Oberg A. L., Keeney G. L., Christianson T. J. H., Low P. S., Knutson K. L., Hartmann L. C., Folate receptor alpha as a tumor target in epithelial ovarian cancer Gynecologic Oncology 2008 108 619 626
303. Konner J. A., Bell-McGuinn K. M., Sabbatini P., Hensley M. L., Tew W. P., Pandit-Taskar N., Vander Els N., Phillips M. D., Schweizer C., Weil S. C., Larson S. M., Old L. J., Farletuzumab, a humanized monoclonal antibody against folate receptor, in epithelial ovarian cancer: a phase I study Clinical Cancer Research 2010 16 21 5288 5295
304. Shih I. M., Davidson B., Pathogenesis of ovarian cancer: clues from selected overexpressed genes Future Oncology 2009 5 10 1641 1657
305. Lim R., Lappas M., Ahmed N., Permezel M., Quinn M. A., Rice G. E., 2D-PAGE of ovarian cancer: analysis of soluble and insoluble fractions using medium-range immobilized pH gradients Biochemical and Biophysical Research Communications 2011 406 3 408 413
306. Moore L. E., Fung E. T., McGuire M., Rabkin C. C., Molinaro A., Wang Z., Zhang F., Wang J., Yip C., Meng X. Y., Pfeiffer R. M., Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population Cancer Epidemiology Biomarkers and Prevention 2006 15 9 1641 1646 (Pubitemid 44497099)
307. Nosov V., Su F., Amneus M., Birrer M., Robins T., Kotlerman J., Reddy S., Farias-Eisner R., Validation of serum biomarkers for detection of early-stage ovarian cancer American Journal of Obstetrics and Gynecology 2009 200 6 639.e1 639.e5
308. Abdullah-Soheimi S. S., Lim B. K., Hashim O. H., Shuib A. S., Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin Proteome Science 2010 8, article no. 58
309. Kodama J., Miyagi Y., Seki N., Tokumo K., Mitsuo Yoshinouchi, Kobashi Y., Okuda H., Kudo T., Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer European Journal of Obstetrics Gynecology and Reproductive Biology 1999 82 1 107 110 (Pubitemid 29042226)
310. Macci A., Lai P., Santona M. C., Pagliara L., Melis G. B., Mantovani G., High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer Gynecologic Oncology 1998 69 3 248 252 (Pubitemid 28289968)
311. Macci A., Madeddu C., Massa D., Astara G., Farci D., Melis G. B., Mantovani G., Interleukin-6 and leptin as markers of energy metabolicchanges in advanced ovarian cancer patients Journal of Cellular and Molecular Medicine 2009 13 9 B 3951 3959
312. Macci A., Madeddu C., Massa D., Mudu M. C., Lusso M. R., Gramignano G., Serpe R., Melis G. B., Mantovani G., Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia Blood 2005 106 1 362 367 (Pubitemid 40967214)
313. Toriola A. T., Grankvist K., Agborsangaya C. B., Lukanova A., Lehtinen M., Surcel H. -M., Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study Annals of Oncology 2011 22 8 1916 1921
314. Chen M., Chen L. M., Lin C. Y., Chai K. X., The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells Biochimica et Biophysica Acta 2008 1783 5 896 903
315. Costa F. P., Batista Junior E. L., Zelmanowicz A., Svedman C., Devenz G., Alves S., da Silva A. S. M., Garicochea B., Prostasin, a potential tumor marker in ovarian cancera pilot study Clinics 2009 64 7 641 644
316. Mok S. C., Chao J., Skates S., Wong K. K., Yiu G. K., Muto M. G., Berkowitz R. S., Cramer D. W., Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology Journal of the National Cancer Institute 2001 93 19 1458 1464 (Pubitemid 32982674)
317. Agarwal R., D'Souza T., Morin P. J., Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity Cancer Research 2005 65 16 7378 7385 (Pubitemid 41161271)
318. D'Souza T., Agarwal R., Morin P. J., Phosphorylation of Claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells Journal of Biological Chemistry 2005 280 28 26233 26240 (Pubitemid 41022220)
319. Davidson B., The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma Cytopathology 2011 22 1 5 21
320. Honda H., Pazin M. J., Ji H., Wernyj R. P., Morin P. J., Crucial roles of Sp1 and epigenetic modifications in the regulation of the cldn4 promoter in ovarian cancer cells Journal of Biological Chemistry 2006 281 30 21433 21444 (Pubitemid 44115482)
321. Kleinberg L., Holth A., Trope C. G., Reich R., Davidson B., Claudin upregulation in ovarian carcinoma effusions is associated with poor survival Human Pathology 2008 39 5 747 757 (Pubitemid 351618309)
322. Li J., Chigurupati S., Agarwal R., Mughal M. R., Mattson M. P., Becker K. G., Wood W. H., Zhang Y., Morin P. J., Possible angiogenic roles for claudin-4 in ovarian cancer Cancer Biology and Therapy 2009 8 19 1806 1814
323. Rangel L. B. A., Agarwal R., D'Souza T., Pizer E. S., Al P. L., Lancaster W. D., Gregoire L., Schwartz D. R., Cho K. R., Morin P. J., Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas Clinical Cancer Research 2003 9 7 2567 2575 (Pubitemid 36842098)
324. Szab I., Kiss A., Schaff Z., Sobel G., Claudins as diagnostic and prognostic markers in gynecological cancer Histology and histopathology 2009 24 12 1607 1615
325. Turunen M., Talvensaari-Mattila A., Soini Y., Santala M., Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma Anticancer Research 2009 29 12 5185 5189
326. Yuan X., Lin X., Manorek G., Howell S. B., Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency BMC Cancer 2011 11 61
327. Bovicelli A., D'Andrilli G., Giordano A., New players in ovarian cancer Journal of Cellular Physiology 2011 226 10 2500 2504
328. Beck H. P., Kohn T., Rubenstein S., Hedberg C., Schwandner R., Hasslinger K., Dai K., Li C., Liang L., Wesche H., Frank B., An S., Wickramasinghe D., Jaen J., Medina J., Hungate R., Shen W., Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents Bioorganic and Medicinal Chemistry Letters 2008 18 3 1037 1041 (Pubitemid 351179347)
329. Bese T., Barbaros M., Baykara E., Guralp O., Cengiz S., Demirkiran F., Sanioglu C., Arvas M., Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer Journal of Gynecologic Oncology 2010 21 4 248 254
330. Choi K. U., Yun J. S., Lee I. H., Heo S. C., Shin S. H., Jeon E. S., Choi Y. J., Suh D. S., Yoon M. S., Kim J. H., Lysophosphatidic acid-induced expression of periostin in stromal cells: prognoistic relevance of periostin expression in epithelial ovarian cancer International Journal of Cancer 2011 128 2 332 342
331. Chou C. H., Wei L. H., Kuo M. L., Huang Y. J., Lai K. P., Chen C. A., Hsieh C. Y., Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF- B pathway by lysophosphatidic acid, an ovarian cancer-activating factor Carcinogenesis 2005 26 1 45 52
332. Jeon E. S., Heo S. C., Lee I. H., Choi Y. J., Park J. H., Choi K. U., Park D. Y., Suh D. S., Yoon M. S., Kim J. H., Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 from human mesenchymal stem cells Experimental and Molecular Medicine 2010 42 4 280 293
333. Kim E. K., Park J. M., Lim S., Choi J. W., Kim H. S., Seok H., Seo J. K., Oh K., Lee D. -S., Kim K. T., Ryu S. H., Suh P. -G., Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells Journal of Biological Chemistry 2011 286 27 24036 24045
334. Murph M., Tanaka T., Liu S., Mills G. B., Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer Clinical Cancer Research 2006 12 22 6598 6602 (Pubitemid 44876826)
335. Oyesanya R. A., Greenbaum S., Dang D., Lee Z., Mukherjee A., Wu J., Dent P., Fang X., Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid Molecular Cancer 2010 9, article no. 8
336. Said N. A., Najwer I., Socha M. J., Fulton D. J., Mok S. C., Motamed K., SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk Neoplasia 2007 9 1 23 35 (Pubitemid 46203932)
337. Sedlkov I., Vvrov J., Toner J., Hanousek L., Lysophosphatidic acid (LPA)a perspective marker in ovarian cancer Tumor Biology 2011 32 2 311 316
338. Seo J. H., Jeong K. J., Oh W. J., Sul H. J., Sohn J. S., Kim Y. K., Cho D. Y., Kang J. K., Park C. G., Lee H. Y., Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin Cancer Letters 2010 288 1 50 56
339. Yu S., Murph M. M., Lu Y., Liu S., Hall H. S., Liu J., Stephens C., Fang X., Mills G. B., Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells Journal of the National Cancer Institute 2008 100 22 1630 1642
340. Abbott K. L., Lim J. M., Wells L., Benigno B. B., McDonald J. F., Pierce M., Identification of candidate biomarkers with cancerspecific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis Proteomics 2010 10 3 470 481
341. Misa B. N., Gengyin Z., Yaqiong L., Novel isoforms of periostin expressed in the human thyroid Japanese Clinical Medicine 2010 1 13 20
342. Gillan L., Matei D., Fishman D. A., Gerbin C. S., Karlan B. Y., Chang D. D., Periostin secreted by epithelial ovarian carcinoma is a ligand for V 3 and V 5 integrins and promotes cell motility Cancer Research 2002 62 18 5358 5364
343. Ruan K., Bao S., Ouyang G., The multifaceted role of periostin in tumorigenesis Cellular and Molecular Life Sciences 2009 66 14 2219 2230
344. Zhu M., Fejzo M. S., Anderson L., Dering J., Ginther C., Ramos L., Gasson J. C., Karlan B. Y., Slamon D. J., Periostin promotes ovarian cancer angiogenesis and metastasis Gynecologic Oncology 2010 119 2 337 344
345. Zhu M., Saxton R. E., Ramos L., Chang D. D., Karlan B. Y., Gasson J. C., Slamon D. J., Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis Molecular Cancer Therapeutics 2011 10 8 1500 1508
346. Bandiera E., Zanotti L., Bignotti E., Romani C., Tassi R., Todeschini P., Tognon G., Ragnoli M., Santin A. D., Gion M., Pecorelli S., Ravaggi A., Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response International Journal of Gynecological Cancer 2009 19 6 1015 1021
347. Batra J., Tan O. L., O'Mara T., Zammit R., Nagle C. M., Clements J. A., Kedda M. A., Spurdle A. B., Kallikrein-related peptidase 10 (KLK10) expression and single nucleotide polymorphisms in ovarian cancer survival International Journal of Gynecological Cancer 2010 20 4 529 536
348. Bayani J., Paliouras M., Planque C., Shan S. J. C., Graham C., Squire J. A., Diamandis E. P., Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer Molecular Oncology 2008 2 3 250 260
349. Borgoo C. A., Kishi T., Scorilas A., Harbeck N., Dorn J., Schmalfeldt B., Schmitt M., Diamandis E. P., Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer Clinical Cancer Research 2006 12 5 1487 1493
350. Emami N., Diamandis E. P., Human tissue kallikreins: a road under construction Clinica Chimica Acta 2007 381 1 78 84 (Pubitemid 46719134)
351. Koh S. C.L., Razvi K., Chan Y. H., Narasimhan K., Ilancheran A., Low J. J., Choolani M., Sahil F., Lutan D., Siddik D., Suwiyoga K., Budiana G., Pradjitmo H., Saleh A. Z., Aziz M. F., Winarto H., Thanh P. V., Hoan N. K.H., Ravichandran I., Dominic N., The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer Archives of Gynecology and Obstetrics 2011 284 1 183 190
352. Kountourakis P., Psyrri A., Scorilas A., Camp R., Markakis S., Kowalski D., Diamandis E. P., Dimopoulos M. A., Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA) Cancer Science 2008 99 11 2224 2229
353. Kountourakis P., Psyrri A., Scorilas A., Markakis S., Kowaiski D., Camp R. L., Diamandis E. P., Dimopoulos M. A., Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis Thrombosis and Haemostasis 2009 101 3 541 546
354. Kuzmanov U., Jiang N., Smith C. R., Soosaipillai A., Diamandis E. P., Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system Molecular amp; Cellular Proteomics 2009 8 4 791 798
355. Luo L. Y., Shan S. J. C., Elliott M. B., Soosaipillai A., Diamandis E. P., Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma Clinical Cancer Research 2006 12 3 742 750 (Pubitemid 43259853)
356. Luo L. Y., Soosaipillai A., Grass L., Diamandis E. P., Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients Tumor Biology 2006 27 5 227 234 (Pubitemid 44260247)
357. Oikonomopoulou K., Batruch I., Smith C. R., Soosaipillai A., Diamandis E. P., Hollenberg M. D., Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid Biological Chemistry 2010 391 4 381 390
358. Oikonomopoulou K., Scorilas A., Michael I. P., Grass L., Soosaipillai A., Rosen B., Murphy J., Diamandis E. P., Kallikreins as markers of disseminated tumour cells in ovarian cancera pilot study Tumor Biology 2006 27 2 104 114
359. Prezas P., Arlt M. J. E., Viktorov P., Soosaipillai A., Holzscheiter L., Schmitt M., Talieri M., Diamandis E. P., Krger A., Magdolen V., Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells Biological Chemistry 2006 387 6 807 811 (Pubitemid 43964805)
360. Shan S. J. C., Scorilas A., Katsaros D., Diamandis E. P., Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects British Journal of Cancer 2007 96 2 362 372 (Pubitemid 46160644)
361. Shan S. J. C., Scorilas A., Katsaros D., Rigault De La Longrais I., Massobrio M., Diamandis E. P., Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols Clinical Chemistry 2006 52 10 1879 1886 (Pubitemid 44470695)
362. Shih I. M., Salani R., Fiegl M., Wang T. L., Soosaipillai A., Marth C., Mller-Holzner E., Gastl G., Zhang Z., Diamandis E. P., Ovarian cancer specific kallikrein profile in effusions Gynecologic Oncology 2007 105 2 501 507 (Pubitemid 46590345)
363. White N. M. A., Chow T. F. F., Mejia-Guerrero S., Diamandis M., Rofael Y., Faragalla H., Mankaruous M., Gabril M., Girgis A., Yousef G. M., Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer British Journal of Cancer 2010 102 8 1244 1253
364. White N. M. A., Mathews M., Yousef G. M., Prizada A., Fontaine D., Ghatage P., Popadiuk C., Dawson L., Doré J. J. E., Human kallikrein related peptidases 6 and 13 in combination with CA125 is a more sensitive test for ovarian cancer than CA125 alone Cancer Biomarkers 2009 5 6 279 287
365. Yousef G. M., Diamandis E. P., The human kallikrein gene family: new biomarkers for ovarian cancer Cancer Treatment and Research 2009 149 165 187
366. Edgell T. A., Barraclough D. L., Rajic A., Dhulia J., Lewis K. J., Armes J. E., Barraclough R., Rudland P. S., Rice G. E., Autelitano D. J., Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer Clinical Science 2010 118 12 717 725
367. Rice G. E., Edgell T. A., Autelitano D. J., Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer Journal of Experimental and Clinical Cancer Research 2010 29 1, article no. 62
368. Wang Z., Hao Y., Lowe A. W., The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation Cancer Research 2008 68 2 492 497 (Pubitemid 351380076)
369. Anderson N. S., Bermudez Y., Badgwell D., Chen R., Nicosia S. V., Bast R. C., Kruk P. A., Urinary levels of Bcl-2 are elevated in ovarian cancer patients Gynecologic Oncology 2009 112 1 60 67
370. Chaudhry P., Srinivasan R., Patel F. D., Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome Oncology Research 2010 18 11-12 549 559
371. Brunmeir R., Lagger S., Seiser C., Histone deacetylase 1 and 2-controlled embryonic development and cell differentiation International Journal of Developmental Biology 2009 53 2-3 275 289
372. Chao K. C., Chang C. C., Yen M. S., Wang P. H., Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells European Journal of Gynaecological Oncology 2010 31 4 402 410
373. Conti C., Leo E., Eichler G. S., Sordet O., Martin M. M., Fan A., Aladjem M. I., Pommier Y., Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage Cancer Research 2010 70 11 4470 4480
374. Haberland M., Montgomery R. L., Olson E. N., The many roles of histone deacetylases in development and physiology: implications for disease and therapy Nature Reviews Genetics 2009 10 1 32 42
375. Hayashi A., Horiuchi A., Kikuchi N., Hayashi T., Fuseya C., Suzuki A., Konishi I., Shiozawa T., Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin International Journal of Cancer 2010 127 6 1332 1346
376. Jeon H. S., Ahn M. Y., Park J. H., Kim T. H., Chun P., Kim W. H., Kim J., Moon H. R., Jung J. H., Kim H. S., Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells International Journal of Oncology 2010 37 2 419 428
377. Lane A. A., Chabner B. A., Histone deacetylase inhibitors in cancer therapy Journal of Clinical Oncology 2009 27 32 5459 5468
378. Luo Y., Jian W., Stavreva D., Fu X., Hager G., Bungert J., Huang S., Qiu Y., Trans-regulation of histone deacetylase activities through acetylation Journal of Biological Chemistry 2009 284 50 34901 34910
379. Ma X., Ezzeldin H. H., Diasio R. B., Histone deacetylase inhibitors: current status and overview of recent clinical trials Drugs 2009 69 14 1911 1934
380. Marks P. A., Xu W. S., Histone deacetylase inhibitors: potential in cancer therapy Journal of Cellular Biochemistry 2009 107 4 600 608
381. Chiocca S., Segré C. V., Regulating the regulators: the post-translational code of class i HDAC1 and HDAC2 Journal of Biomedicine and Biotechnology 2011 2011 15
382. Takai N., Narahara H., Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer Obstetrics and Gynecology International 2010 2010 8
383. Ueda T., Takai N., Nishida M., Nasu K., Narahara H., Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells International Journal of Molecular Medicine 2007 19 2 301 308
384. Willis-Martinez D., Richards H. W., Timchenko N. A., Medrano E. E., Role of HDAC1 in senescence, aging, and cancer Experimental Gerontology 2010 45 4 279 285
385. Wilting R. H., Yanover E., Heideman M. R., Jacobs H., Horner J., Van Der Torre J., Depinho R. A., Dannenberg J. H., Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis EMBO Journal 2010 29 15 2586 2597
386. Yamaguchi T., Cubizolles F., Zhang Y., Reichert N., Kohler H., Seiser C., Matthias P., Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression Genes and Development 2010 24 5 455 469
387. Bartels C. L., Tsongalis G. J., Mini-reviews micrornas:novel biomarkers for human cancer Clinical Chemistry 2009 55 4 623 631
388. Cowden Dahl K. D., Dahl R., Kruichak J. N., Hudson L. G., The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells Neoplasia 2009 11 11 1208 1215
389. Creighton C. J., Fountain M. D., Yu Z., Nagaraja A. K., Zhu H., Khan M., Olokpa E., Zariff A., Gunaratne P. H., Matzuk M. M., Anderson M. L., Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers Cancer Research 2010 70 5 1906 1915
390. Li Z., Hu S., Wang J., Cai J., Xiao L., Yu L., Wang Z., MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells Gynecologic Oncology 2010 119 1 125 130
391. Lu J., Getz G., Miska E. A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B. L., Mak R. H., Ferrando A. A., Downing J. R., Jacks T., Horvitz H. R., Golub T. R., MicroRNA expression profiles classify human cancers Nature 2005 435 7043 834 838 (Pubitemid 40839735)
392. Rosenfeld N., Aharonov R., Meiri E., Rosenwald S., Spector Y., Zepeniuk M., Benjamin H., Shabes N., Tabak S., Levy A., Lebanony D., Goren Y., Silberschein E., Targan N., Ben-Ari A., Gilad S., Sion-Vardy N., Tobar A., Feinmesser M., Kharenko O., Nativ O., Nass D., Perelman M., Yosepovich A., Shalmon B., Polak-Charcon S., Fridman E., Avniel A., Bentwich I., Bentwich Z., Cohen D., Chajut A., Barshack I., MicroRNAs accurately identify cancer tissue origin Nature Biotechnology 2008 26 4 462 469 (Pubitemid 351501813)
393. Sorrentino A., Liu C. G., Addario A., Peschle C., Scambia G., Ferlini C., Role of microRNAs in drug-resistant ovarian cancer cells Gynecologic Oncology 2008 111 3 478 486
394. Yang H., Kong W., He L., Zhao J. J., O'Donnell J. D., Wang J., Wenham R. M., Coppola D., Kruk P. A., Nicosia S. V., Cheng J. Q., MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN Cancer Research 2008 68 2 425 433 (Pubitemid 351380068)
395. Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., Liang S., Leminen A., Deng S., Smith L., Johnstone C. N., Chen X. M., Liu C. G., Huang Q., Katsaros D., Calin G. A., Weber B. L., Btzow R., Croce C. M., Coukos G., Zhang L., MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer Cancer Research 2008 68 24 10307 10314
396. Zhang L., Volinia S., Bonome T., Calin G. A., Greshock J., Yang N., Liu C. G., Giannakakis A., Alexiou P., Hasegawa K., Johnstone C. N., Megraw M. S., Adams S., Lassus H., Huang J., Kaur S., Liang S., Sethupathy P., Leminen A., Simossis V. A., Sandaltzopoulos R., Naomoto Y., Katsaros D., Gimotty P. A., DeMichele A., Huang Q., Btzow R., Rustgi A. K., Weber B. L., Birrer M. J., Hatzigeorgiou A. G., Croce C. M., Coukos G., Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer Proceedings of the National Academy of Sciences of the United States of America 2008 105 19 7004 7009 (Pubitemid 351754520)
397. LoPiccolo J., Blumenthal G. M., Bernstein W. B., Dennis P. A., Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resistance Updates 2008 11 1-2 32 50
398. Altomare D. A., Hui Q. W., Skele K. L., De Rienzo A., Klein-Szanto A. J., Godwin A. K., Testa J. R., AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth Oncogene 2004 23 34 5853 5857 (Pubitemid 39093031)
399. Dent P., Grant S., Fisher P. B., Curiel D. T., PI3K: a rational target for ovarian cancer therapy? Cancer Biology and Therapy 2009 8 1 27 30
400. Fan X., Ross D. D., Arakawa H., Ganapathy V., Tamai I., Nakanishi T., Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors Biochemical Pharmacology 2010 80 6 811 818
401. Harasawa M., Yasuda M., Hirasawa T., Miyazawa M., Shida M., Muramatsu T., Douguchi K., Matsui N., Takekoshi S., Kajiwara H., Osamura R. Y., Mikami M., Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma Acta Histochemica et Cytochemica 2011 44 2 113 118
402. Rattan R., Giri S., Hartmann L. C., Shridhar V., Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner Journal of Cellular and Molecular Medicine 2011 15 1 166 178
403. Trinh X. B., Van Dam P. A., Dirix L. Y., Vermeulen P. B., Tjalma W. A. A., The rationale for mTOR inhibition in epithelial ovarian cancer Expert Opinion on Investigational Drugs 2009 18 12 1885 1891
404. Arao S., Suwa H., Mandai M., Tashiro H., Miyazaki K., Okamura H., Nomura H., Hiai H., Fukumoto M., Expression of multidrug resistance gene and localization of P- glycoprotein in human primary ovarian cancer Cancer Research 1994 54 5 1355 1359
405. Gréen H., Sderkvist P., Rosenberg P., Horvath G., Peterson C., mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy Clinical Cancer Research 2006 12 3 I 854 859 (Pubitemid 43259868)
406. Richardson A., Kaye S. B., Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resistance Updates 2005 8 5 311 321 (Pubitemid 41677714)
407. Baekelandt M. M., Holm R., Nesland J. M., Tropé C. G., Kristensen G. B., P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer Anticancer Research 2000 20 2 B 1061 1067 (Pubitemid 30240677)
408. Chenevix-Trench G., Johnatty S. E., Beesley J., Paul J., Fereday S., Spurdle A. B., webb P. M., Byth K., Marsh S., McLeod H., Harnett P. R., Brown R., Defazio A., ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy Clinical Cancer Research 2008 14 17 5594 5601
409. Hille S., Rein D. T., Riffelmann M., Neumann R., Sartorius J., Pftzner A., Kurbacher C. M., Schndorf T., Breidenbach M., Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer Anti-Cancer Drugs 2006 17 9 1041 1044 (Pubitemid 44454781)
410. Duan Z., Brakora K. A., Seiden M. V., Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal resistance in human ovarian cancer cells Molecular Cancer Therapeutics 2004 3 7 833 838 (Pubitemid 39193765)
411. Xing H., Wang S., Weng D., Chen G., Yang X., Zhou J., Xu G., Lu Y., Ma D., Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids Oncology Reports 2007 17 1 117 122
412. Miettinen S., Grnman S., Ylikomi T., Inhibition of P-glycoprotein- mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure Anticancer Drugs 2009 20 4 267 276
413. Zahedi P., de Souza R., Huynh L., Piquette-Miller M., Allen C., Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer Molecular Pharmaceutics 2011 8 1 260 269
414. Yang Y., Wang Z., Li M., Lu S., Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells Journal of Huazhong University of Science and Technology 2009 29 2 239 242
415. Hiss D. C., Gabriels G. A., Folb P. I., Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells Cancer Cell International 2007 7, article no. 5
416. Grimm C., Polterauer S., Zeillinger R., Tong D., Heinze G., Wolf A., Natter C., Reinthaller A., Hefler L. A., Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer Anticancer Research 2010 30 9 3487 3491
417. Ludwig A. H., Kupryjaczyk J., Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Clinical Cancer Research 2006 12 20, part 1 6204 6205 (Pubitemid 44703788)
418. Johnatty S. E., Beesley J., Paul J., Fereday S., Spurdle A. B., webb P. M., Byth K., Marsh S., McLeod H., Harnett P. R., Brown R., Defazio A., Chenevix-Trench G., ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy Clinical Cancer Research 2008 14 17 5594 5601
419. Ikeda K., Sakai K., Yamamoto R., Hareyama H., Tsumura N., Watari H., Shimizu M., Minakami H., Sakuragi N., Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer International Journal of Gynecological Cancer 2003 13 6 776 784 (Pubitemid 38235222)
420. Lu L., Katsaros D., Wiley A., Rigault De La Longrais I. A., Puopolo M.,
421. Matsuo K., Eno M. L., Ahn E. H., Shahzad M., Im D. D., Rosenshein N. B., Sood A. K., Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer American Journal of Clinical Oncology 2010 34 5 488 493
422. Peng C., Zhang X., Yu H., Wu D., Zheng J., Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer International Journal of Gynecological Cancer 2011 21 2 280 288